Recent advances in dermal wound healing: biomedical device approaches

References

• Boyce ST, Warden GD. Principles and practices for treatment of cutaneous wounds with cultured skin substitutes. Am. J. Surg.183(4), 445–456 (2002).
   PubMed Web of Science ®Google Scholar
• Phillips TJ. Current approaches to venous ulcers and compression. Dermatol. Surg.27(7), 611–621 (2001).
   PubMed Web of Science ®Google Scholar
• Sweitzer SM, Fann SA, Borg TK, Baynes JW, Yost MJ. What is the future of diabetic wound care? Diabetes Educ.32(2), 197–210 (2006).
   PubMed Web of Science ®Google Scholar
• Clark RA. Fibrin and wound healing. Ann. NY Acad. Sci.936, 355–367 (2001).
   PubMed Web of Science ®Google Scholar
• Ehrenreich M, Ruszczak Z. Update on tissue-engineered biological dressings. Tissue Eng.12(9), 2407–2424 (2006).
   PubMedGoogle Scholar
• MacNeil S. Progress and opportunities for tissue-engineered skin. Nature445(7130), 874–880 (2007).
   PubMed Web of Science ®Google Scholar
• Martin P. Wound healing – aiming for perfect skin regeneration. Science276(5309), 75–81 (1997).
   PubMed Web of Science ®Google Scholar
• Hrabchak C, Flynn L, Woodhouse KA. Biological skin substitutes for wound cover and closure. Expert Rev. Med. Devices3(3), 373–385 (2006).
   PubMed Web of Science ®Google Scholar
• Clark RA, Ghosh K, Tonnesen MG. Tissue engineering for cutaneous wounds. J. Invest. Dermatol.127(5), 1018–1029 (2007).
   PubMed Web of Science ®Google Scholar
• Gosh K, Clark RAF. Wound repair: basic biology of tissue engineering. In: Principles of Tissue Engineering (3rd edition). Lanza A, Langer R, Vacanti JP (Eds). Elsevier/Academic Press, Amsterdam, The Netherlands (2007).
   Google Scholar
• Goldman R. Growth factors and chronic wound healing: past, present, and future. Adv. Skin Wound Care17(1), 24–35 (2004).
   PubMedGoogle Scholar
• Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell91(4), 439–442 (1997).
   PubMed Web of Science ®Google Scholar
• Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol.23(1), 47–55 (2005).
   PubMed Web of Science ®Google Scholar
• Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol.17, 463–516 (2001).
   PubMed Web of Science ®Google Scholar
• Metcalfe AD, Ferguson MW. Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration. J. R. Soc. Interface4(14), 413–437 (2007).
   PubMed Web of Science ®Google Scholar
• Greenhalgh DG. Consequences of excessive scar formation: dealing with the problem and aiming for the future. Wound Repair Regen.15, S2–S5 (2007).
   PubMed Web of Science ®Google Scholar
• Kose O, Waseem A. Keloids and hypertrophic scars: are they two different sides of the same coin? Dermatol. Surg.34(3), 336–346 (2008).
   PubMed Web of Science ®Google Scholar
• Bayat A, McGrouther DA, Ferguson MWJ. Skin scarring. Br. Med. J.326(7380), 88–92 (2003).
   PubMed Web of Science ®Google Scholar
• Tuan TL, Nichter LS. The molecular basis of keloid and hypertrophic scar formation. Mol. Med. Today4(1), 19–24 (1998).
   PubMedGoogle Scholar
• Armour A, Scott PG, Tredget EE. Cellular and molecular pathology of HTS: basis for treatment. Wound Repair Regen.15, S6–S17 (2007).
   PubMed Web of Science ®Google Scholar
• Ferguson MWJ, O’Kane S. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Philos. Trans. R. Soc. Lond. B. Biol. Sci.359(1445), 839–850 (2004).
   PubMed Web of Science ®Google Scholar
• Ghahary A, Shen YJ, Nedelec B, Wang RJ, Scott PG, Tredget EE. Collagenase production is lower in post-burn hypertrophic scar fibroblasts than in normal fibroblasts and is reduced by insulin-like growth factor-1. J. Invest. Dermatol.106(3), 476–481 (1996).
   PubMed Web of Science ®Google Scholar
• Kloeters O, Tandara A, Mustoe TA. Hypertrophic scar model in the rabbit ear: a reproducible model for studying scar tissue behavior with new observations on silicone gel sheeting for scar reduction. Wound Repair Regen.15, S40–S45 (2007).
   Google Scholar
• Liang Z, Engrav LH, Muangman P et al. Nerve quantification in female red Duroc pig (FRDP) scar compared with human hypertrophic scar. Burns30(1), 57–64 (2004).
   PubMed Web of Science ®Google Scholar
• Phillips TJ. New skin for old: developments in biological skin substitutes. Arch. Dermatol.134(3), 344–349 (1998).
   PubMedGoogle Scholar
• Singer AJ, Clark RA. Cutaneous wound healing. N. Engl. J. Med.341(10), 738–746 (1999).
   PubMed Web of Science ®Google Scholar
• Hutmacher DW, Ng KW, Khor HL. Skin tissue engineering Part 1 – review. In: Biodegradable Systems in Tissue Engineering and Regenerative Medicine. Reis RL, Romin JS (Eds). Routledge, NY, USA, 509–528 (2004).
   Google Scholar
• Steed DL, Donohoe D, Webster MW, Lindsley L; Diabetic Ulcer Study Group. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J. Am. Coll. Surg.183(1), 61–64 (1996).
   PubMed Web of Science ®Google Scholar
• Brem H, Sheehan P, Boulton AJ. Protocol for treatment of diabetic foot ulcers. Am. J. Surg.187(5A), S1–S10 (2004).
   PubMedGoogle Scholar
• Griffiths M, Ojeh N, Livingstone R, Price R, Navsaria H. Survival of Apligraf in acute human wounds. Tissue Eng.10(7–8), 1180–1195 (2004).
   PubMedGoogle Scholar
• Omar AA, Mavor AI, Jones AM, Homer-Vanniasinkam S. Treatment of venous leg ulcers with Dermagraft. Eur. J. Vasc. Endovasc. Surg.27(6), 666–672 (2004).
   PubMed Web of Science ®Google Scholar
• Phillips TJ, Manzoor J, Rojas A et al. The longevity of a bilayered skin substitute after application to venous ulcers. Arch. Dermatol.138(8), 1079–1081 (2002).
   PubMed Web of Science ®Google Scholar
• Wisser D, Steffes J. Skin replacement with a collagen based dermal substitute, autologous keratinocytes and fibroblasts in burn trauma. Burns29(4), 375–380 (2003).
   PubMed Web of Science ®Google Scholar
• Falanga V, Margolis D, Alvarez O et al. ; Human Skin Equivalent Investigators Group. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Arch. Dermatol.134(3), 293–300 (1998).
   PubMed Web of Science ®Google Scholar
• Nunery WR. Risk of prion transmission with the use of xenografts and allografts in surgery. Ophthal. Plast. Reconstr. Surg.17(6), 389–394 (2001).
   PubMed Web of Science ®Google Scholar
• Jones I, Currie L, Martin R. A guide to biological skin substitutes. Br. J. Plast. Surg.55(3), 185–193 (2002).
   PubMedGoogle Scholar
• Greenleaf G, Hansbrough JF. Current trends in the use of allograft skin for patients with burns and reflections on the future of skin banking in the United States. J. Burn Care Rehabil.15(5), 428–431 (1994).
   PubMedGoogle Scholar
• Hodde JP, Johnson CE. Extracellular matrix as a strategy for treating chronic wounds. Am. J. Clin Dermatol.8(2), 61–66 (2007).
   PubMed Web of Science ®Google Scholar
• Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J. Vasc. Surg.41(5), 837–843 (2005).
   PubMed Web of Science ®Google Scholar
• Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv. Skin Wound Care18(5 Pt 1), 258–266 (2005).
   PubMedGoogle Scholar
• Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen.16(5), 585–601 (2008).
   PubMed Web of Science ®Google Scholar
• Giancotti FG, Ruoslahti E. Integrin signaling. Science285(5430), 1028–1032 (1999).
   PubMed Web of Science ®Google Scholar
• Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care24(3), 483–488 (2001).
   PubMed Web of Science ®Google Scholar
• Fu X, Li X, Cheng B, Chen W, Sheng Z. Engineered growth factors and cutaneous wound healing: success and possible questions in the past 10 years. Wound Repair Regen.13(2), 122–130 (2005).
   PubMed Web of Science ®Google Scholar
• Upton Z, Cuttle L, Noble A et al. Vitronectin: growth factor complexes hold potential as a wound therapy approach. J. Invest. Dermatol.128(6), 1535–1544 (2008).
   PubMed Web of Science ®Google Scholar
• Kricker JA, Towne CL, Firth SM, Herington AC, Upton Z. Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology144(7), 2807–2815 (2003).
   PubMed Web of Science ®Google Scholar
• Hollier BG, Kricker JA, Van Lonkhuyzen DR, Leavesley DI, Upton Z. Substrate-bound insulin-like growth factor (IGF)-I-IGF binding protein-vitronectin-stimulated breast cell migration is enhanced by coactivation of the phosphatidylinositide 3-kinase/AKT pathway by av-integrins and the IGF-I receptor. Endocrinology149(3), 1075–1090 (2008).
   PubMed Web of Science ®Google Scholar
• Van Lonkhuyzen DR, Hollier BG, Shooter GK, Leavesley DI, Upton Z. Chimeric vitronectin:insulin-like growth factor proteins enhance cell growth and migration through co-activation of receptors. Growth Factors25(5), 295–308 (2007).
   PubMed Web of Science ®Google Scholar
• Rubin C, Gur G, Yarden Y. Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res.15, 66–71 (2005).
   PubMed Web of Science ®Google Scholar
• Ehrbar M, Djonov VG, Schnell C et al. Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ. Res.94(8), 1124–1132 (2004).
   PubMed Web of Science ®Google Scholar
• Sakiyama-Elbert SE, Panitch A, Hubbell JA. Development of growth factor fusion proteins for cell-triggered drug delivery. FASEB J.15(7), 1300–1302 (2001).
   PubMed Web of Science ®Google Scholar
• Schmoekel HG, Weber FE, Schense JC, Gratz KW, Schawalder P, Hubbell JA. Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol. Bioeng.89(3), 253–262 (2005).
   PubMed Web of Science ®Google Scholar
• Schense JC, Hubbell JA. Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. Bioconjug. Chem.10(1), 75–81 (1999).
   PubMed Web of Science ®Google Scholar
• Lehnhardt M, Hauser J, Daigeler A et al. The use of a variant PDGF incorporated into fibrin sealant in burn patients undergoing autologous meshed skin grafting: a Phase 2a clinical study. Wound Repair Regen.17(2), A13 (2009).
   Google Scholar
• Huldt-Nystrom T, Meuleneire F, Acton C. Xelma®, an advanced wound treatment for venous ulcers: a European perspective. Wounds UK4(1), 106–110 (2008).
   Google Scholar
• Rosso F, Marino G, Giordano A, Barbarisi M, Parmeggiani D, Barbarisi A. Smart materials as scaffolds for tissue engineering. J. Cell Physiol.203(3), 465–470 (2005).
   PubMed Web of Science ®Google Scholar
• Fedorovich NE, Alblas J, de Wijn JR, Hennink WE, Verbout AJ, Dhert WJ. Hydrogels as extracellular matrices for skeletal tissue engineering: state-of-the-art and novel application in organ printing. Tissue Eng.13(8), 1905–1925 (2007).
   PubMedGoogle Scholar
• Langer R, Tirrell DA. Designing materials for biology and medicine. Nature428(6982), 487–492 (2004).
   PubMed Web of Science ®Google Scholar
• Nicodemus GD, Bryant SJ. Cell encapsulation in biodegradable hydrogels for tissue engineering applications. Tissue Eng. Part B Rev.14(2), 149–165 (2008).
   PubMed Web of Science ®Google Scholar
• Winter GD. Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig. Nature193, 293–294 (1962).
   PubMed Web of Science ®Google Scholar
• Cushing MC, Anseth KS. Materials science. Hydrogel cell cultures. Science316(5828), 1133–1134 (2007).
   PubMed Web of Science ®Google Scholar
• Ehrbar M, Rizzi SC, Hlushchuk R et al. Enzymatic formation of modular cell-instructive fibrin analogs for tissue engineering. Biomaterials28(26), 3856–3866 (2007).
   PubMed Web of Science ®Google Scholar
• Shu XZ, Ghosh K, Liu Y et al. Attachment and spreading of fibroblasts on an RGD peptide-modified injectable hyaluronan hydrogel. J. Biomed. Mater. Res. A68(2), 365–375 (2004).
   PubMed Web of Science ®Google Scholar
• Ghosh K, Ren XD, Shu XZ, Prestwich GD, Clark RA. Fibronectin functional domains coupled to hyaluronan stimulate adult human dermal fibroblast responses critical for wound healing. Tissue Eng.12(3), 601–613 (2006).
   PubMedGoogle Scholar
• Serban MA, Liu Y, Prestwich GD. Effects of extracellular matrix analogues on primary human fibroblast behavior. Acta Biomater.4(1), 67–75 (2008).
   PubMed Web of Science ®Google Scholar
• Schneider A, Garlick JA, Egles C. Self-assembling peptide nanofiber scaffolds accelerate wound healing. PLoS ONE3(1), e1410 (2008).
   PubMed Web of Science ®Google Scholar
• Gelain F, Horii A, Zhang S. Designer self-assembling peptide scaffolds for 3-D tissue cell cultures and regenerative medicine. Macromol. Biosci.7(5), 544–551 (2007).
   PubMed Web of Science ®Google Scholar
• Ehrbar M, Rizzi SC, Schoenmakers RG et al. Biomolecular hydrogels formed and degraded via site-specific enzymatic reactions. Biomacromolecules8(10), 3000–3007 (2007).
   PubMed Web of Science ®Google Scholar
• Rizzi SC, Xie Y, Dawson R et al. Injectable biomimetic matrices to guide impaired wound healing. Wound Repair Regen.16(4), A62–A63 (2008).
   Google Scholar
• Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature453(7193), 314–321 (2008).
   PubMed Web of Science ®Google Scholar
• Atiyeh BS. Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. Aesthetic Plast. Surg.31(5), 468–492 (2007).
   PubMed Web of Science ®Google Scholar
• Reish RG, Eriksson E. Scar treatments: preclinical and clinical studies. J. Am. Coll. Surg.206(4), 719–730 (2008).
   PubMed Web of Science ®Google Scholar
• Li-Tsang CWP, Lau JCM, Choi J, Chan CCC, Jianan L. A prospective randomized clinical trial to investigate the effect of silicone gel sheeting (Cica-Care) on post-traumatic hypertrophic scar among the Chinese population. Burns32(6), 678–683 (2006).
   PubMed Web of Science ®Google Scholar
• Chernoff WG, Cramer H, Su-Huang S. The efficacy of topical silicone gel elastomers in the treatment of hypertrophic scars, keloid scars, and post-laser exfoliation erythema. Aesthetic Plast. Surg.31(5), 495–500 (2007).
   PubMed Web of Science ®Google Scholar
• Mustoe TA. Evolution of silicone therapy and mechanism of action in scar management. Aesthetic Plast. Surg.32(1), 82–92 (2008).
   PubMed Web of Science ®Google Scholar
• Berman B, Perez OA, Konda S et al. A review of the biologic effects, clinical efficacy, and safety of silicone elastomer sheeting for hypertrophic and keloid scar treatment and management. Dermatol. Surg.33(11), 1291–1303 (2007).
   PubMed Web of Science ®Google Scholar
• Occleston NL, O’Kane S, Goldspink N, Ferguson MWJ. New therapeutics for the prevention and reduction of scarring. Drug Discovery Today13(21–22), 973–981 (2008).
   PubMed Web of Science ®Google Scholar
• Niessen FB, Spauwen PHM, Robinson PH, Fidler V, Kon M. The use of silicone occlusive sheeting (Sil-K) and silicone occlusive gel (epiderm) in the prevention of hypertrophic scar formation. Plast. Reconstr. Surg.102(6), 1962–1972 (1998).
   PubMed Web of Science ®Google Scholar
• Gold MH, Foster TD, Adair MA, Burlison K, Lewis T. Prevention of hypertrophic scars and keloids by the prophylactic use of topical silicone gel sheets following a surgical procedure in an office setting. Dermatol. Surg.27(7), 641–644 (2001).
   PubMed Web of Science ®Google Scholar
• O’Brien L, Pandit A. Silicon gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst. Rev.(1), CD003826 (2006).
   PubMedGoogle Scholar
• Shah M, Foreman D, Ferguson M. Neutralization of TGF-β(1) and TGF-β(2) or exogenous addition of TGF-β(3) to cutaneous rat wounds reduces scarring. J. Cell Sci.108, 985–1002 (1995).
   PubMed Web of Science ®Google Scholar
• Occleston NL, Laverty HG, O’Kane S, Ferguson MWJ. Prevention and reduction of scarring in the skin by transforming growth factor b 3 (TGF b3): from laboratory discovery to clinical pharmaceutical. J. Biomater. Sci. Polym. Ed.19(8), 1047–1063 (2008).
   PubMed Web of Science ®Google Scholar
• Hamrell MR. An overview of the US regulatory environment for drug-device and biologic-device combination products. Drug Inf. J.40(1), 23–32 (2006).
   Web of Science ®Google Scholar
• McGuckin M, Waterman R, Brooks J et al. Validation of venous leg ulcer guidelines in the United States and United Kingdom. American J. Surgery183(2), 132–137 (2002).
   PubMed Web of Science ®Google Scholar
• Herdrich BJ, Lind RC, Liechty KW. Multipotent adult progenitor cells: their role in wound healing and the treatment of dermal wounds. Cytotherapy10(6), 543–550 (2008).
   PubMed Web of Science ®Google Scholar
• Zhu N, Warner RM, Simpson C et al. Treatment of burns and chronic wounds using a new cell transfer dressing for delivery of autologous keratinocytes. European J. Plastic Surgery28, 319–330 (2005).
   Google Scholar
• Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A Phase III randomized placebo-controlled double-blind study. Diabetes Care21(5), 822–827 (1998).
   PubMed Web of Science ®Google Scholar
• Fu X, Shen Z, Chen Y et al. Randomised placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns. Lancet352(9141), 1661–1664 (1998).
   PubMed Web of Science ®Google Scholar